Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.

By
Andrea Surnit
September 8, 2026
4 min

MDSpire News

Background

Enteroviruses are significant pathogens in pediatric populations, causing a range of diseases from mild illnesses to severe conditions like meningitis and myocarditis. The complexity of enterovirus infections, coupled with their genetic diversity, poses substantial challenges for effective treatment and prevention strategies.

Data Highlights

No numerical data available.

Key Findings

Enteroviruses account for approximately 58% of meningitis or encephalitis cases in children.
Reverse transcription–polymerase chain reaction (RT-PCR) has a sensitivity of over 95% for EV diagnosis.
Current treatment for EV infections is primarily supportive, as no antiviral drug is approved for routine clinical use.
Investigational antiviral agents have shown limited efficacy and many remain in preclinical stages.
The inactivated EV-A71 vaccine has shown efficacy against severe HFMD but does not provide cross-protection against other enteroviruses.